• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    11/28/23 2:44:53 PM ET
    $ALLG
    $ARGX
    $AVO
    $BDRX
    Automotive Aftermarket
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLG alert in real time by email

    Shares of SenesTech, Inc. (NASDAQ:SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.

    SenesTech company priced a public offering of around 3.8 million shares of common stock at $1.30 per share, alongside warrants for additional shares.

    SenesTech shares declined 50.3% to $0.9189 on Tuesday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • IceCure Medical Ltd (NASDAQ:ICCM) jumped 90% to $1.44 after the company announced the latest release of a study in a series of independent studies of ProSense published in peer-reviewed journals demonstrating safety and efficacy.
    • RedHill Biopharma Ltd. (NASDAQ:RDHL) gained 90% to $1.90. Redhill Biopharma announced the FDA has granted five years' market exclusivity for Talicia.
    • HNR Acquisition Corp (NASDAQ:HNRA) gained 67% to $2.89 after the company gave a business update.
    • Fusion Fuel Green PLC (NASDAQ:HTOO) rose 39.6% to $1.25.
    • Carbon Revolution Public Limited Company (NASDAQ:CREV) gained 30% to $33.55 after Craig-Hallum initiated coverage on the stock with a Buy rating and a $84 price target.
    • ESGL Holdings Limited (NASDAQ:ESGL) gained 29.6% to $1.1590 as the company disclosed a multi-year contract renewal with Singapore Refining Company Private Limited.
    • Bitfarms Ltd. (NASDAQ:BITF) gained 24.5% to $1.3200. The company announced upgrades for its mining fleet.
    • Arcimoto, Inc. (NASDAQ:FUV) rose 23.7% to $1.0892.
    • Gyre Therapeutics, Inc. (NASDAQ:GYRE) gained 23.5% to $25.85.
    • Farfetch Limited (NYSE:FTCH) gained 21.9% to $2.0850 following a report suggesting the company's founder may be in talks to take the company private.
    • Avidity Biosciences, Inc. (NASDAQ:RNA) surged 21.3% to $7.47 after the company reported expansion of cardiovascular collaboration with Bristol Myers Squibb.
    • Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) climbed 20.4% to $2.7209.
    • SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) gained 19.1% to $24.73. The FDA approved SpringWorks Therapeutics’ Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who require systemic treatment.
    • PDD Holdings Inc. (NASDAQ:PDD) shares gained 18% to $138.90 following third-quarter results.
    • CleanSpark, Inc. (NASDAQ:CLSK) rose 13.3% to $6.32.
    • Cheche Group Inc. (NASDAQ:CCG) surged 12.3% to $6.17.
    • Clearway Energy, Inc. (NYSE:CWEN) gained 11.4% to $25.48. Clearway Energy will replace Veritiv in the S&P SmallCap 600.
    • LendingClub Corporation (NYSE:LC) climbed 10.6% to $6.17. Piper Sandler initiated coverage on LendingClub with an Overweight rating and announced a price target of $8.
    • Lilium N.V. (NASDAQ:LILM) gained 10.4% to $1.0050. Lilium announced it received EASA Design Organization Approval.
    • Marathon Digital Holdings, Inc. (NASDAQ:MARA) climbed 8.2% to $12.21.
    • The Carlyle Group Inc. (NASDAQ:CG) rose 5.1% to $34.48. Carlyle Group will replace ICU Medical in the S&P MidCap 400, effective prior to the open of trading on Nov. 30.

    Losers

    • Tharimmune, Inc. (NASDAQ:THAR) shares fell 72.8% to $0.9499. Tharimmune priced its $10 million public offering 10 million common shares at $1 per share.
    • Cabaletta Bio, Inc. (NASDAQ:CABA) fell 31.9% to $12.73 after the FDA said it was investigating a risk of T-cell malignancies in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
    • Acelyrin, Inc. (NASDAQ:SLRN) declined 31.6% to $5.94 after the company announced an error in its Phase 2b/3 trial for izokibep. The company said the error has been addressed and the dosing sequence has been fixed.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) fell 31.2% to $3.5195 after the company announced an offering of 1,397,849 Class A units at an assumed public offering price of $2.79 per Class A unit.
    • iBio, Inc. (NASDAQ:IBIO) fell 28% to $0.2078 after the company announced a 20-to-1 reverse stock split.
    • CohBar, Inc. (NASDAQ:CWBR) fell 23.2% to $0.6901.
    • Gracell Biotechnologies Inc. (NASDAQ:GRCL) declined 13.6% to $4.6650. Gracell Biotechnologies recently announced it received FDA clearance of the IND application for the Phase 1/2 clinical trial of FasTCAR-T GC012F for the treatment of refractory systemic lupus erythematosus.
    • Erasca, Inc. (NASDAQ:ERAS) declined 11.6% to $1.98 after announcing program updates.
    • argenx SE (NASDAQ:ARGX) fell 10.5% to $443.67 after the company reported the ADVANCE-SC study evaluating VYVGART Hytrulo in adults with primary immune thrombocytopenia did not meet primary or secondary endpoints.
    • Allego N.V. (NASDAQ:ALLG) declined 9.6% to $1.2650.
    • Luminar Technologies, Inc. (NASDAQ:LAZR) fell 9.6% to $2.3750.
    • Mission Produce, Inc. (NASDAQ:AVO) fell 7.1% to $8.24. Roth MKM maintained Mission Produce with a Buy and lowered the price target from $18 to $12.5.
    • Cool Company Ltd. (NYSE:CLCO) shares fell 5.3% to $12.72 after reporting results for the third quarter.

     

     

    Now Read This: Top 5 Risk Off Stocks Which Could Rescue Your Portfolio This Month

    Get the next $ALLG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLG
    $ARGX
    $AVO
    $BDRX

    CompanyDatePrice TargetRatingAnalyst
    PDD Holdings Inc.
    $PDD
    4/17/2026$121.00Neutral → Buy
    Arete
    PDD Holdings Inc.
    $PDD
    3/27/2026$136.00Neutral → Buy
    Nomura
    Atrium Therapeutics Inc.
    $RNA
    3/11/2026$25.00Overweight
    Wells Fargo
    argenx SE
    $ARGX
    3/10/2026Hold → Buy
    Deutsche Bank
    MARA Holdings Inc.
    $MARA
    2/27/2026Buy → Neutral
    H.C. Wainwright
    The Carlyle Group Inc.
    $CG
    2/24/2026$67.00Outperform
    RBC Capital Mkts
    MARA Holdings Inc.
    $MARA
    2/9/2026$8.00Underweight
    Morgan Stanley
    Erasca Inc.
    $ERAS
    1/27/2026$16.00Outperform
    Mizuho
    More analyst ratings

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PDD Holdings upgraded by Arete with a new price target

    Arete upgraded PDD Holdings from Neutral to Buy and set a new price target of $121.00

    4/17/26 9:26:04 AM ET
    $PDD
    EDP Services
    Technology

    PDD Holdings upgraded by Nomura with a new price target

    Nomura upgraded PDD Holdings from Neutral to Buy and set a new price target of $136.00

    3/27/26 8:43:00 AM ET
    $PDD
    EDP Services
    Technology

    Wells Fargo initiated coverage on Atrium Therapeutics with a new price target

    Wells Fargo initiated coverage of Atrium Therapeutics with a rating of Overweight and set a new price target of $25.00

    3/11/26 8:36:38 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acentra Health Chief AI Officer Sean Harrison Named to NVTC AI50

    MCLEAN, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions company dedicated to accelerating better health outcomes for government and commercial clients and the populations they serve, today announced that Sean Harrison, Chief AI Officer, has been named an honoree in the Northern Virginia Technology Council (NVTC) inaugural 2026 AI50 Awards. The awards recognize the companies and leaders across the National Capital Region who are moving artificial intelligence from concept to real-world impact. Selected from over 160 nominations across Northern Virginia, Harrison was honored in the AI50 Executives category, which highlights visionary leaders shaping

    4/24/26 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    OIO Group Completes De Tomaso Business Combination, Establishing New Control and Strategic Platform for Growth

    SINGAPORE, April 23, 2026 (GLOBE NEWSWIRE) -- OIO Group (NASDAQ:OIO) ("OIO" or the "Company") today announced the completion of its previously announced business combination with De Tomaso Automobili Holdings Limited ("De Tomaso"), resulting in a change of control of the Company. This milestone represents a transformational step for OIO as it advances its strategy to build a portfolio of distinctive, high-value operating businesses anchored in brand heritage, engineering excellence, and long-term value creation. As a result of the closing of the transaction, De Tomaso's founder, Norman Choi, becomes the controlling shareholder of OIO Group, positioning the Company under leadership with d

    4/23/26 4:38:00 PM ET
    $ESGL
    $OIO
    Environmental Services
    Utilities

    Fusion Fuel Appoints Uranium Investor James Passin as Chairman and Appoints Frederico Figueira de Chaves as Chief Executive Officer

    Passin, recently appointed to the Board, brings over two decades of institutional uranium investment expertise to help lead the Company's strategic direction Frederico Figueira de Chaves appointed CEO, bringing deep knowledge of the Company's strategy and operations Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- Fusion Fuel Green PLC (NASDAQ:HTOO) ("Fusion Fuel" or the "Company"), a leading provider of full-service energy engineering, advisory, and utility solutions, today announced changes to its Board of Directors (the "Board") and senior management. James Passin, who was recently appointed to the Board, has been appointed Chairman of the Board, and Frederico Figueira de Chaves has been ap

    4/23/26 8:30:00 AM ET
    $HTOO
    Industrial Machinery/Components
    Energy

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Raday Gilead

    4 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    4/22/26 6:09:14 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kenney Stephanie

    4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)

    4/22/26 5:54:12 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hughes Steven George

    4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)

    4/22/26 5:54:06 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLG
    $ARGX
    $AVO
    $BDRX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by LendingClub Corporation

    SCHEDULE 13G - LendingClub Corp (0001409970) (Subject)

    4/24/26 12:34:19 PM ET
    $LC
    Finance: Consumer Services
    Finance

    SEC Form SCHEDULE 13G filed by LendingClub Corporation

    SCHEDULE 13G - LendingClub Corp (0001409970) (Subject)

    4/24/26 12:30:22 PM ET
    $LC
    Finance: Consumer Services
    Finance

    SEC Form DEF 14A filed by The Carlyle Group Inc.

    DEF 14A - Carlyle Group Inc. (0001527166) (Filer)

    4/23/26 4:08:37 PM ET
    $CG
    Investment Managers
    Finance

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Globalharvest Holdings Venture Ltd bought $2,583,903 worth of shares (217,274 units at $11.89), increasing direct ownership by 2% to 9,987,882 units (SEC Form 4)

    4 - Mission Produce, Inc. (0001802974) (Issuer)

    3/17/26 4:54:51 PM ET
    $AVO
    Farming/Seeds/Milling
    Consumer Staples

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ALLG
    $ARGX
    $AVO
    $BDRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 27, 2023 - FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

    For Immediate Release: November 27, 2023 Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive. The tumor

    11/27/23 5:34:21 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for OGSIVEO issued to SPRINGWORKS THERAPEUTICS INC

    Submission status for SPRINGWORKS THERAPEUTICS INC's drug OGSIVEO (ORIG-1) with active ingredient NIROGACESTAT has changed to 'Approval' on 11/27/2023. Application Category: NDA, Application Number: 217677, Application Classification: Type 1 - New Molecular Entity

    11/27/23 5:34:04 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Quality Industrial Corp. Announces CEO Transition

    Carsten Kjems Falk Appointed Chief Executive Officer SAN FRANCISCO, CA, April 23, 2026 (GLOBE NEWSWIRE) -- Quality Industrial Corp. (the "Company") (OTCID: QIND), an industrial and energy-focused company providing comprehensive solutions for the liquefied petroleum gas ("LPG") industry, today announced the appointment of Carsten Kjems Falk as Chief Executive Officer. Mr. Falk will continue to serve as Chief Financial Officer and a director of the Company. The appointment follows the resignation of John-Paul Backwell as Chief Executive Officer, for personal and health reasons. Mr. Backwell will continue to serve as a director of the Company. Mr. Falk has served as the Company's Interim Ch

    4/23/26 8:00:00 AM ET
    $HTOO
    Industrial Machinery/Components
    Energy

    YipitData Appoints ZoomInfo Founder and CEO Henry Schuck to Board of Directors to Support Next Phase of Growth

    Schuck brings deep expertise in scaling data-driven technology platforms and building category-defining companies YipitData, the leading provider of alternative data-driven market intelligence for institutional investors, retailers, consumer brands, and enterprises, today announced that Henry Schuck, Founder and Chief Executive Officer of ZoomInfo (NASDAQ:GTM), has joined its Board of Directors. Schuck brings more than two decades of experience building and scaling data-driven technology platforms. He founded ZoomInfo in 2007 and led its transformation from an early-stage startup into a category-defining B2B intelligence platform, culminating in a successful public listing. Under his le

    4/13/26 9:00:00 AM ET
    $CG
    $GTM
    Investment Managers
    Finance
    Computer Software: Prepackaged Software
    Technology

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Financials

    Live finance-specific insights

    View All

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

    The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum acceleratesCryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract AwardCAESAREA, Israel, April 21, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in

    4/21/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Carlyle Credit Income Fund Schedules Second Quarter Financial Results and Investor Conference Call

    NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund ("we," "us," "our," "CCIF" or the "Fund") (NYSE:CCIF) announced today that it will release financial results after market close on Tuesday, May 19, 2026, for its second quarter of 2026. CCIF will host a conference call at 10:00 a.m. EST on Wednesday, May 20, 2026, to discuss the results. The conference call will be available via public webcast via a link on Carlyle Credit Income Fund's website at www.carlylecreditincomefund.com and will also be available on the website soon after the call's completion. About Carlyle Credit Income Fund Carlyle Credit Income Fund (NYSE:CCIF) is an externally managed closed-end f

    4/20/26 4:01:00 PM ET
    $CCIF
    $CG
    Finance/Investors Services
    Finance
    Investment Managers

    $ALLG
    $ARGX
    $AVO
    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fusion Fuel Green PLC

    SC 13G/A - Fusion Fuel Green PLC (0001819794) (Subject)

    12/11/24 4:02:05 PM ET
    $HTOO
    Industrial Machinery/Components
    Energy

    SEC Form SC 13D filed by Fusion Fuel Green PLC

    SC 13D - Fusion Fuel Green PLC (0001819794) (Filed by)

    12/6/24 6:06:39 PM ET
    $HTOO
    Industrial Machinery/Components
    Energy

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care